Trans-aTTom: Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen—To offer more? (aTTom) trial.

John Bartlett, Dennis Sgroi, Kai Treuner, Yi Zhang, Tammy Piper, Ranelle C. Salunga, Ikhlaaq Ahmed, Kristen M Basnet, Elena Brachtel, Sarah Pirrie, Catherine A. Schnabel, Daniel William Rea

Research output: Contribution to journal › Abstract › peer-review

Fingerprint

Dive into the research topics of 'Trans-aTTom: Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen—To offer more? (aTTom) trial.'. Together they form a unique fingerprint.

Medicine & Life Sciences